1. Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

   • Stefanie L. Groenland
   • J. M. Janssen
   • N. Steeghs

   Original Article 22 March 2023 Pages: 447 - 456

   

2. Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India

   • Ankit Patel
   • Niraj Bhatt
   • Maulik Doshi

   Original Article 24 April 2023 Pages: 457 - 468

   

3. Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors

   • Noboru Yamamoto
   • Takafumi Koyama
   • Kentaro Yamazaki

   Original Article 04 May 2023 Pages: 469 - 480

   

4. Associations of plasma aprepitant and its N-dealkylated metabolite with cachexia status and clinical responses in head and neck cancer patients

   • Yusuke Suzuki
   • Takafumi Naito
   • Junichi Kawakami

   Original Article 04 May 2023 Pages: 481 - 490

   

5. Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor

   • Seong Jang
   • Bill Strickland
   • Jan Van Tornout

   Original Article Open access 06 May 2023 Pages: 491 - 499

   

6. The prevalence of end-of-life chemotherapy and targeted therapy in Japan, assessed using a health claims database

   • Masami Tsuchiya
   • Taku Obara
   • Nariyasu Mano

   Original Article 08 May 2023 Pages: 501 - 506

   

7. Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy

   • Samantha K. Korver
   • Joanne M. Bowen
   • Janet K. Coller

   Original Article Open access 10 May 2023 Pages: 507 - 521

   

8. Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers

   • Chaoying Hu
   • Yanping Zhang
   • Lan Zhang

   Clinical Trial Report 11 May 2023 Pages: 523 - 529